Plasma and tissue resveratrol concentrations and pharmacological activity

Drugs under Experimental and Clinical Research

Volumn 24, Issue 3, 1998, Pages 133-138

  Bertelli, A ^a   Bertelli, A A E ^a   Gozzini, A ^b   Giovannini, L ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b ASL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUND; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; GRAPE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; THROMBOCYTE AGGREGATION; WINE;

ANIMALS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; STILBENES; TIME FACTORS; WINE;

EID: 0031771271     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Pont V., Pezet R. Relation between the chemical structure and the biological activity of hydroxystilbene against Botrytis cinerea. J. Phytopathol., 130, 1, 1990.
2. Jeandet P., Bessis R., Sbaghi M. Production of the phytoalexin resveratrol by grape berries as a response to Botrytis attack under natural conditions. Physiologie de la Vigne, O.I.V., Paris, 1993.
3. Langcake P., Pryce R.J. The production of resveratrol and the viniferins by grapevines in response to ultraviolet irradiation. Phytochemistry, 16, 1193, 1977.
4. Langcake P., Pryce R.J. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol., 9, 77, 1976.
5. Frankel E.N., Kanner Y., German Y.B., Parks E., Kinsella Y.E. Inhibition of oxidation of human low-density of lipoprotein by phenolic substances in red wine. Lancet, 341, 454, 1993.
6. Pace-Asciak C.R., Ronnova O., Hahn E., Diamandis E.P., Goldberg D.M. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin. Chim. Acta, 246, 163, 1996.
7. Frankel E.N., Waterhouse A.L., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet, 341, 1103, 1993.
8. Hertog M.G.L., Fernskens E.Y., Hollman P.C., Katan M., Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet, 342, 1007, 1993.
9. Hertog M.G.L. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch. Intern. Med., 155, 381, 1995.
10. Renaud S., De Lorgeril N. Wine, alcohol, platelets and the French Paradox for coronary heart disease. Lancet, 339, 1523, 1992.
11. Kimura Y., Okuda H., Arici S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochem. Biophys. Acta, 834, 275, 1985.
12. Belguendouz L., Fremont L., Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoprotems. Biochem. Pharmacol., 53, 1347, 1997.
13. Jang M., Cai L., Udeani G.O., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218, 1997.
14. Bertelli A.A.E., Giovannini L., Giannessi D., Panichi V., Bertelli A. Anti-aggregating activity of trans-and cis-resveratrol. Fibrinolysis, 10 (Suppl. 1), 35, 1996.
15. 2 production in vitro. Acta Pharmacologica Sinica, 11, 527, 1990.
16. Ferrera M.E., Corsi M., Giovannini L., et al. Activity of resveratrol on endothelial adhesion molecules. 7th Interscience World Conference on Inflammation. Geneva May 19-21, 1997. Abst., Int. J. Tissue React XIX, 121, 1997.
17. Chen C.K., Pace-Asciak C.R. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen. Pharmacol., 27, 366, 1996.
18. Born G.V., Cross M.J. The aggregation of blood platelets. J. Physiol., 168, 178, 1963.
19. Moreno-Manas M., Pleixatas R. Dehydroxacetic acid chemistry. A new synthesis of resveratrol, a phytoalexin of Vitis vinifera. Ann. Quim., 81, 157, 1985.